On Monday, Novartis (NYSE:NVS) announced positive topline results from the Phase III PSMAddition trial, which showed that its targeted radioligand therapy/RLT, Pluvicto (lutetium (177Lu ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Monday positive topline results from a pre-specified interim analysis of the Phase III PSMAddition trial for Pluvicto plus hormone therapy ...

Dr Petros Grivas discusses updates in biomarker-driven therapies and emerging treatment strategies from the STAMPEDE, AMPLITUDE, and PSMAddition trials.

Petros Grivas, MD, shares key updates from ASCO 2025, focusing on advances in prostate cancer across disease stages. He highlights promising results from the AMPLITUDE trial showing a radiographic ...

Novartis Says Phase III PSMAddition Trial Met Its Primary Endpoint. Published: June 2, 2025 at 1:39 a.m. ET. Share. Resize. About Dow Jones Newswires.

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...

PSMAddition (NCT04720157) is a Phase III, open-label, prospective, 1:1 randomized study comparing the efficacy and safety of Pluvicto in combination with SoC (ARPI + ADT) ...

This is the third positive read-out for Pluvicto in a phase III trial, following the VISION and PSMAfore studies. Results from PSMAddition in mHSPC show potential for treatment in an earlier setting ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for ...

Novartis Pharma AG. Ad hoc announcement pursuant to Art. 53 LR. At interim analysis, PSMAddition trial met its primary endpoint showing statistically significant and clinically meaningful benefit for ...